✦ LIBER ✦

A phase I trial of recombinant gamma interferon in patients with cancer

✍ Scribed by Kenneth A. Foon; Stephen A. Sherwin; Paul G. Abrams; Henry C. Stevenson; Pamela Holmes; Annette E. Maluish; Robert K. Oldham; Ronald B. Herberman

Publisher: Springer-Verlag
Year: 1985
Tongue: English
Weight: 461 KB
Volume: 20
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf00205575

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant gamma interferon in advanced

Recombinant gamma interferon in advanced breast cancer: A phase II trial

✍ Hyman B. Muss; Mary Caponera; Patricia J. Zekan; Don V. Jackson; John J. Stuart; 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 365 KB

Fifteen patients with advanced carcinoma of the breast who had failed prior chemotherapy, were treated with recombinant gamma interferon at a dose of 2mg/m2 (1mg = 2.4 X 10(7) international units) intravenously for five consecutive days every other week. The median patient age was 51 and all patient

A Phase II combination trial with recomb

A Phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer

✍ Fiedler, W. ;Zeller, W. ;Peimann, C. -J. ;Weh, H. -J. ;Hossfeld, D. K. 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 779 KB

A phase I-II trial of the combination of

A phase I-II trial of the combination of recombinant leukocyte a interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma

✍ Edward T. Creagan; Charles L. Loprinzi; David L. Ahmann; Daniel J. Schaid 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB 👁 2 views

Results of a phase-II clinical trial on

Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma

✍ E. M. Lemmel; M. Franke; W. Gaus; P. W. Hartl; P. H. Hofschneider; K. Miehlke; K 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 552 KB

In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the se

Subcutaneous recombinant gamma interfero

Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects

✍ John A. Thompson; W. Welby Cox; Catherine G. Lindgren; Carolyn Collins; Kathryn 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 750 KB

Recombinant gamma interferon (ry-IFN) was administered s. c. daily to 26 patients with advanced cancer. Patients were assigned to one of six doses: 0.5, 1, 2, 4, 6, or 8 million units (MU)/m 2 per d. The major toxicities were an influenza-like syndrome and fever, seen in all patients. Dose limiting

Phase II trial of recombinant interferon

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

✍ Raoudha Mahjoubi; Mounir Bachouchi; Jean-Nicolas Munck; Pierre Busson; Jamel Gas 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB

## Abstract The presence of Epstein–Barr virus (EBV) genomes in the DNA of tumor cells of undifferentiated carcinoma of nasopharyngeal type (UCNT), associated with significant lymphocytic infiltration of tumor led to therapeutic trials with interferon (IFN) because of its antiviral, antiproliferati